echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > J Headache Pain: Migraine Medication Use and Cost Trends 2017-2020

    J Headache Pain: Migraine Medication Use and Cost Trends 2017-2020

    • Last Update: 2022-09-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Migraines are a burden


    Recently, a research paper was published in The Journal of Headache and Pain, the authoritative journal in the field of anesthesia pain, which aims to investigate the changes in usage rates and cost trends


    This retrospective cross-sectional study surveyed data


    The sample size of the study ranged from 161369 (2017) to 240,330 (2020) patients


    The study shows that the use of migraine drugs has shifted since 2017-2020, and the increase in the use of CGRP monoclonal antibodies is an important reason for the increase in costs


    Original source:

    Jennifer L.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.